Dear Colleagues,

This Special Issue is the second edition of the previous Special Issue entitled the "Current Challenge and Future Advances for Lung Cancer: Genetics, Instrumental Diagnosis and Treatment"
(https://www.mdpi.com/journal/cancers/special_issues/Lung_Cancer_Genetics_Instrumental_Diagnosis_Treatment).

Lung cancer remains a malignancy with a poor prognosis, with only 20% of patients reporting an overall survival rate longer than five years from diagnosis. The prognosis of these patients has not significantly improved, despite the developments in the definition of the genetic evolution of lung cancer, the greater accuracy of diagnostic procedures, and the refinement of treatments using multimodal regimens, including surgery, radiotherapy, and systemic therapy (chemotherapy, immunotherapy, and targeted therapy).

Therefore, this Special Issue will include data on potential new diagnostic and therapeutic discoveries that aim to improve the prognosis of lung cancer patients. In particular, the most recent acquisitions regarding the biology of lung cancer (both non-small- and small-cell lung cancer), such as specific gene mutations, genomic heterogeneity, and the discovery of new biomarkers, will be highlighted.

Furthermore, we welcome papers that cover the following topics: (1) developments in diagnostic methods for the early diagnosis of lung cancer, including radiological studies; (2) studies or reviews on innovative aspects of lung cancer treatment in the fields of surgery, radiotherapy, and medical treatments; and (3) studies on real life experiences of multimodal approaches.

Ultimately, for this Special Issue, we welcome basic translational and clinical research papers, studies on cancer biomarkers, professional opinions, and reviews in the broad field of lung cancer diagnosis and therapy in the following categories:

• Lung cancer diagnosis.
• Lung cancer metastases (with an emphasis on CNS metastases).
• Lung cancer surgery.
• Lung cancer radiotherapy.
• Lung cancer chemotherapy.
• Lung cancer target therapies.
• Lung cancer immunotherapy.
• Elderly populations with lung cancer.
• Side effects of lung cancer therapies.
• Surrogate biomarkers in lung cancer.
• Preclinical and translational research in lung cancer.

Dr. Giovanni Vicidomini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Onco is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• lung cancer
• diagnosis
• treatment
• therapy
• cancer metastases (with an emphasis on CNS metastases)
• surgery
• radiotherapy
• chemotherapy
• target therapies
• immunotherapy
• elderly with lung cancer
• side effects
• surrogate biomarkers
• preclinical research
• translational research